What is Semaglutide?
Semaglutide is a synthetic peptide studied in metabolic research as a long-acting GLP-1 receptor agonist. Its backbone is based on human GLP-1(7-37), with about 94% sequence identity to the native hormone, and it carries targeted modifications that protect it from enzymatic degradation and allow it to bind serum albumin.
As a selective single-receptor agonist, semaglutide is a common reference compound in incretin research and the baseline against which dual agonists such as tirzepatide and triple agonists such as retatrutide are compared. It has been studied extensively in published literature, including clinical research. This overview covers its structure, mechanism, research areas and laboratory handling.
This article is a scientific overview for laboratory researchers. The research-grade semaglutide supplied by Prime Peptide Solutions is sold strictly for in-vitro laboratory research. It is not approved for human use and is not for human or animal consumption.
Background: The GLP-1 Signaling System
GLP-1 and its receptor
GLP-1 (glucagon-like peptide-1) is an incretin hormone secreted by intestinal L-cells in response to nutrients. One of its bioactive forms, GLP-1(7-37), acts on the GLP-1 receptor (GLP-1R), a class B G protein-coupled receptor expressed on pancreatic beta cells, in the central nervous system, in the gut and in several peripheral tissues. GLP-1R signaling has been studied in connection with glucose-dependent insulin secretion, glucagon release, gastric emptying and appetite-related signaling pathways.
Why native GLP-1 is short-lived
Native GLP-1 is inactivated within minutes. The enzyme dipeptidyl peptidase-4 (DPP-4) removes an N-terminal dipeptide, and the small peptide is also cleared rapidly by the kidneys. These limits drove the design of stabilized GLP-1 analogs.
Where GIP fits
GIP (glucose-dependent insulinotropic polypeptide) is the second incretin hormone and acts on its own receptor, GIPR. Semaglutide does not meaningfully engage GIPR, which is the main pharmacological difference between it and dual agonists such as tirzepatide.
Structure and Design
Semaglutide keeps the overall GLP-1(7-37) backbone but adds three targeted changes:
- Aib at position 8: the alanine at position 8 is replaced by alpha-aminoisobutyric acid (Aib), a non-coded amino acid that makes the N-terminus resistant to DPP-4 cleavage.
- Lys34Arg substitution: the lysine at position 34 is replaced by arginine, leaving Lys26 as the only lysine available for side-chain attachment.
- C18 fatty diacid on Lys26: the Lys26 side chain carries an 18-carbon fatty diacid, connected through a gamma-glutamic acid and OEG linker. This lipid group binds reversibly to serum albumin.
Albumin binding slows renal clearance and shields the peptide from degradation. Together with DPP-4 resistance, this gives semaglutide an elimination half-life of about 7 days (roughly 165 hours) in published pharmacokinetic data, compared with minutes for native GLP-1.
Molecule at a Glance
- Backbone: human GLP-1(7-37), about 94% sequence identity
- Key modifications: Aib8, Lys34Arg, C18 fatty diacid on Lys26
- Molecular formula: C187H291N45O59
- Molecular weight: about 4113.6 Da
- Half-life: about 7 days (roughly 165 hours) in published pharmacokinetic data
- Receptor target: GLP-1 receptor (GLP-1R)
Proposed Mechanism of Action
Selective GLP-1 receptor agonism
Semaglutide binds and activates the GLP-1 receptor. Receptor activation couples to Gs proteins, stimulates adenylyl cyclase and raises intracellular cAMP. In pancreatic beta cells, cAMP signaling through protein kinase A and Epac2 potentiates insulin secretion only when glucose is elevated, the glucose dependence that defines incretin signaling. GLP-1R activation is also studied in laboratory models for its link to glucose-dependent suppression of glucagon release, which may involve indirect signaling through neighboring islet cells.
Albumin binding and receptor exposure
Because the C18 diacid binds serum albumin reversibly, most circulating semaglutide is albumin-bound, and only the free fraction interacts with the receptor at any moment. The bound pool acts as a slowly released reservoir. This has a practical consequence for in-vitro work: the albumin or serum content of an assay medium can shift the apparent potency of the molecule, so assay conditions should be reported alongside any potency figure.
How Semaglutide Compares
Semaglutide vs tirzepatide
Tirzepatide is a dual GIP and GLP-1 receptor agonist built on the GIP sequence, with a C20 fatty diacid and a half-life of about 5 days. Semaglutide engages GLP-1R alone. The semaglutide vs tirzepatide comparison sets the two side by side, and the tirzepatide research overview explains its imbalanced and biased receptor profile.
Semaglutide vs retatrutide
Retatrutide is a triple agonist of the GIP, GLP-1 and glucagon receptors, with a C20 fatty diacid and a half-life of about 6 days. Its glucagon-receptor activity brings energy-expenditure and hepatic-metabolism pathways into the same molecule. See the semaglutide vs retatrutide comparison and the retatrutide research overview.
Semaglutide vs AOD-9604
AOD-9604 is a modified fragment of the C-terminal region of human growth hormone. It is structurally unrelated to GLP-1, is not an incretin receptor agonist, and is studied mainly in connection with lipid metabolism in adipose tissue models. The AOD-9604 vs semaglutide comparison outlines how the two differ as research tools.
Current Research Areas
In cell and animal models, semaglutide is used to study:
- Glucose-dependent insulin secretion: beta-cell lines and isolated islets are used to examine GLP-1R-driven cAMP signaling and insulin release.
- Incretin signaling and receptor pharmacology: as a well-characterized single agonist, semaglutide serves as a reference ligand in receptor-binding and cAMP assays.
- Gastric emptying: animal models examine how GLP-1R activation affects gastric motility.
- Appetite-related signaling pathways: GLP-1R expression in the hypothalamus and brainstem makes these regions a focus of rodent studies.
- Hepatic metabolism: rodent models are used to examine liver lipid metabolism under sustained GLP-1R activation.
Comparative studies pair semaglutide with dual and triple agonists to isolate what GLP-1R activity contributes.
Stability and Laboratory Handling
General handling
Semaglutide is supplied as a lyophilized powder and is reconstituted with bacteriostatic water (0.9% benzyl alcohol in sterile water), sold separately in 3 mL and 10 mL vials. Lyophilized vials are stored cold at 2-8 °C, or at -20 °C for long-term storage, and protected from light. The reconstituted solution is kept refrigerated at 2-8 °C, is not frozen and thawed repeatedly, and is not shaken. GLP-1 SM comes in a 10mg vial: the semaglutide reconstitution guide covers diluent volumes, and the GLP-1 SM calculator preset works out solution concentration.
Verifying Quality
Identity and purity should be confirmed on a batch-specific Certificate of Analysis. HPLC separates the peptide from related impurities to give a purity figure, while mass spectrometry confirms identity by checking that the observed mass matches the expected molecular weight of about 4113.6 Da. Our guide on reading a peptide COA explains each field, and understanding HPLC and mass spec covers how the two methods work together.
Frequently Asked Research Questions
What type of agonist is semaglutide?
A selective GLP-1 receptor agonist. It activates the GLP-1 receptor alone, unlike dual agonists such as tirzepatide or triple agonists such as retatrutide.
Why does semaglutide carry Aib at position 8?
Native GLP-1 is cleaved at its N-terminus by DPP-4. Replacing the alanine at position 8 with Aib makes semaglutide resistant to that cleavage.
What is the purpose of the Lys34Arg substitution?
Replacing the lysine at position 34 with arginine leaves Lys26 as the only lysine, so the C18 fatty diacid side chain is attached at a single, defined site.
Why does semaglutide have a long half-life?
DPP-4 resistance from Aib8 and reversible albumin binding through the C18 fatty diacid together slow degradation and clearance, giving a half-life of about 7 days in published pharmacokinetic data.
Is semaglutide approved for human use?
The research-grade semaglutide sold by Prime Peptide Solutions is not approved for human use. It is supplied only as a reference material for in-vitro laboratory research and is not for human or animal consumption. The compound has been studied extensively in published literature, including clinical research, but the material in this catalog is not a medicine and should not be regarded as equivalent to any approved medicine.
How is GLP-1 SM related to semaglutide?
GLP-1 SM is our catalog listing for research-grade semaglutide, supplied as a lyophilized powder in a 10mg vial for in-vitro laboratory research.
Conclusion
Semaglutide is a selective GLP-1 receptor agonist built on the human GLP-1(7-37) backbone, protected against DPP-4 by Aib at position 8 and extended by a C18 fatty diacid on Lys26 that binds serum albumin. Its single-receptor profile makes it a standard reference compound in incretin research and a baseline for dual and triple agonists. For laboratories, the relevant considerations are its well-defined structure, careful cold storage and batch-level verification by HPLC and mass spectrometry.
Disclaimer: This article is provided for educational and research purposes only. It summarizes publicly available scientific literature and does not constitute medical advice. Semaglutide and all peptide compounds sold by Prime Peptide Solutions are intended strictly for laboratory research, are not approved for human use, and are not for human or animal consumption. Researchers are responsible for compliance with all applicable regulations in their jurisdiction.
References & Further Reading
- PubMed: Current peer-reviewed semaglutide literature
- PubMed: Semaglutide structure and albumin binding
- PubMed: GLP-1 receptor signaling research
- Related: Semaglutide vs Tirzepatide: A Research Comparison
Research-Grade Semaglutide
In our catalog, research-grade semaglutide is listed as GLP-1 SM (semaglutide), supplied as a lyophilized powder in a 10mg vial. Identity and purity are documented by HPLC and mass spectrometry, and the Certificate of Analysis for every batch is published on our COA page.
Sold strictly for in-vitro laboratory research. Not for human or animal consumption.